Recent developments across technology, industry, policy, and research highlight new directions for sleep medicine in the second quarter of 2026. Drawing on AASM’s State of Sleep Q2 2026 updates, this overview summarizes how key trends are evolving.
Consumer tech integrates deeper into sleep care pathways
Large technology and consumer companies are expanding beyond standalone sleep features to more integrated sleep health experiences and partnerships. For example, in June, Amazon launched Sleep Studio, a bedtime content hub for families delivered via Echo devices with stories and guided meditations from Calm and Headspace. Samsung updated its Galaxy Watch features to turn nightly biometric and sleep data into actionable guidance for healthier routine decisions. In addition, health integration took a step forward when Dreem Health’s virtual sleep clinic became the first sleep service offered through Amazon’s Health Benefits Connector, connecting eligible users to insurance-covered sleep care via the e-commerce platform. Meanwhile, ResMed and Ōura announced a partnership in May to better reach people with unrecognized sleep problems by linking consumer wearable data with formal sleep education and care pathways.
These developments show how consumer tech is merging with clinical channels, potentially changing how patients engage with sleep care beyond traditional healthcare settings.
At-home diagnostics and monitoring gain momentum
There continues to be a rapid expansion of at-home sleep testing and remote patient monitoring tools. The FDA’s clearance of Sunrise Air, a chin-worn sensor that tracks jaw movements to detect breathing disturbances, brings another convenient home sleep apnea test to the market. Onera Health’s home PSG system was integrated into a cloud-based platform, Somnoware, enabling clinicians to conduct full polysomnography in patients’ homes with streamlined workflow management. Telehealth provider OpenLoop also launched a new service offering at-home sleep apnea diagnostics, expanding its platform through a partnership with Happy Sleep and giving its network of providers access to these tests.
Additionally, strong consumer interest in at-home screening is evident: Sleep Cycle reported over 150,000 people registering for its upcoming sleep apnea risk detection app in advance of launch. These innovations and uptake signals indicate that home-based sleep assessments and continuous monitoring are becoming mainstream. Sleep clinicians will need to integrate these tools and data into care, while ensuring that convenience does not compromise accuracy or appropriate follow-up for patients.
Industry consolidation and commercialization accelerate
Mergers, acquisitions, and financing deals in Q2 point to a rapidly consolidating sleep health marketplace. In June, Eli Lilly completed its acquisition of Centessa Pharmaceuticals, adding Centessa’s orexin agonist pipeline for narcolepsy and other sleep disorders to Lilly’s portfolio. This follows Lilly’s investment in the weight-loss/GLP-1 space and underscores big pharma’s strategic interest in sleep therapeutics. Medical device leader ResMed similarly broadened its reach with acquisitions and alliances: It announced in May and completed in June the acquisition of Noctrix Health to gain an FDA-cleared, non-pharmacologic restless legs syndrome therapy. Beacon Biosignals and CleveMed — both key players in digital EEG and home sleep testing — merged in June, combining their expertise in at-home diagnostics and brain monitoring technology to strengthen their market position. On the consumer side, Ōura Health, maker of the popular smart ring, confidentially filed for an IPO after an $11B valuation. ResMed’s partnership with Ōura similarly reflects the blurring of lines between consumer wellness products and clinical care.
Altogether, these moves suggest a wave of consolidation and commercialization in the sleep industry. Larger companies are snapping up specialized startups and forming strategic partnerships, likely aiming to build integrated platforms that can deliver end-to-end solutions and scale sleep services to larger populations.
Promising therapies and devices advance through the pipeline
Multiple innovative treatments and devices for sleep disorders made significant strides this quarter, bringing new options closer to patients. In Q2, the FDA granted orphan drug designation to Alkermes’ alixorexton, an oral orexin-2 receptor agonist, for narcolepsy and hypersomnia indications. New data also emerged: A Phase 2 trial of alixorexton in narcolepsy type 2 reported positive results in June, and Takeda’s oral orexin agonist oveporexton (TAK-861) showed improvements in daily functioning and symptoms for narcolepsy type 1.
Progress is also evident in non-PAP therapies for obstructive sleep apnea (OSA). Apnimed secured up to $150 million in financing to prepare for a potential U.S. launch of AD109, its investigational once-daily OSA pill, should FDA approval come through. The company also published positive Phase 3 trial results for AD109, validating its unique neuromuscular mechanism in treating OSA. Meanwhile, Incannex received a U.S. patent for its IHL-42X oral OSA medication (which has Fast Track status and is in Phase 2 trials) and launched a new late-stage trial, reinforcing industry confidence in pharmacotherapy options for OSA.
In the realm of metabolic therapy, GLP-1 medications have started to intersect with sleep: The FDA approved Eli Lilly’s orforglipron (branded Foundayo), an oral GLP-1 weight-loss pill, which is also being studied for OSA. Additionally, Lilly reported that its next-generation triple-agonist retatrutide produced substantial weight loss and improvements in OSA severity in clinical trials.
These developments exemplify how multiple pipelines — from orexin agonists and OSA pills to metabolic therapies — are converging on sleep disorders.
Navigating an evolving insurance and reimbursement landscape
Significant policy and payer developments in Q2 highlight the challenges and changes impacting sleep practices, from reimbursement pressures to attempts at administrative simplification. At the federal level, Medicare physician payment remains under scrutiny: Policymakers acknowledge that base rates have not kept pace with rising practice costs, fueling financial instability and prompting calls for an inflation-linked update. In parallel, CMS is pushing to modernize the burdensome prior authorization process, proposing new rules to digitize and streamline pre-approvals — a move supported by the AASM due to its potential to ease care delays and administrative overhead. However, concerns remain about the increasing role of automation in payment decisions: The Electronic Frontier Foundation has filed a lawsuit challenging CMS’s pilot use of an AI-driven prior authorization system (WISeR), citing lack of transparency and potential to delay needed care. Meanwhile, some private insurers signaled modest progress by standardizing data and submission requirements for many prior authorizations, an industry-led step toward reducing paperwork and delays.
Within sleep medicine, the AASM has responded with resources to help practices respond to restrictive reimbursement policies and align with payer and policy expectations with an updated Remote Services Monitoring Guide. Additionally, the AASM released a new Claims Denial Navigation Guide to help providers prevent and address insurance denials, and it submitted formal comments to CMS endorsing efforts to improve electronic prior authorization and interoperability.
As policy changes gradually unfold — from the No Surprises Act’s dispute resolution updates to forthcoming Medicare GLP-1 Bridge program for drug coverage — sleep specialists will need to stay engaged in advocacy and adapt workflows, ensuring patient care isn’t compromised by payment complexities.
Prioritizing trust and oversight amid rapid innovation
As new technologies and information channels proliferate, Q2 underscored the growing need for vigilance and guidance to maintain trust and ethical standards in sleep medicine and healthcare at large.
On one hand, AI tools and digital platforms continue to be embraced: A version of ChatGPT for Clinicians was launched in April, offering a free AI assistant for physicians to help with documentation and research tasks.
On the other hand, professional groups are emphasizing caution. The AASM’s AI in Sleep Medicine Committee published guidance on maintaining a “healthy degree of AI skepticism,” advising clinicians on how to evaluate algorithm performance metrics so they remain informed gatekeepers rather than passive adopters. The AMA also warned of threats like deepfake technology and called for frameworks to protect physicians from impersonation.
Maintaining patient trust is another challenge highlighted this quarter. A Medscape survey found nearly half of physicians feel patients trust their treatment advice less now than in the past, reflecting growing public wariness of expert guidance. This trend coincides with data showing that younger Americans increasingly turn to online influencers and non-physician personalities for health information.
For sleep professionals, these shifts emphasize the importance of clear patient communication and reliable information channels, as well as proactive engagement in public education to counter misinformation. The broader context, including rising anxiety levels and pervasive wellness “hype” online, calls for sleep experts to champion science-based guidance and collaborate on credible content to help patients navigate a noisy health information landscape.
Summary
Taken together, the Q2 trends in sleep medicine point to accelerating change and increasing complexity in the field. The quarter saw heightened consolidation of companies and collaborations, signaling a rapidly commercializing and converging sleep industry. Consumer technologies are weaving more tightly into clinical practice, and a robust biotech pipeline is poised to deliver novel therapies and devices to clinicians and patients. At the same time, the policy and reimbursement environment remains in flux, mixing reforms and friction that can shape daily practice. Importantly, thought leaders are emphasizing the need for careful oversight and sustained public trust as innovation moves at a fast pace. Monitoring these developments will be crucial as sleep medicine continues to integrate further with technology, broader health domains, and evolving healthcare systems, requiring clinicians to adapt and collaborate in an interconnected landscape.
This article was developed using artificial intelligence and underwent human review and revision to ensure accuracy and clarity.
